![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, April 15, 2017 11:09:35 AM
While shareholders in NTRP are counting down the days until the Ph2b study results are released there is another group that is highly interested in the outcome.
Dr. Alkon gave the Keynote address at the Sachs Neuroscience and Biopartnering & Investment Forum (3-27-17) to some two hundred plus attendees, many of whom were representatives of the largest Pharmaceutical companies in the world. The CEOs of a number of NTRP competitors were also there to give their own company presentations. (see attendee list at bottom)
By design the Sachs Forum was set up to connect businesses involved in AD and Parkinson disease research with Big Pharmas that are looking at what is in the development pipeline for possible partnerships or buyouts.
Representative of many major Investment Funds were likewise prospecting for promising companies.
The large and small players in the AD research field are vitally interested in their counterpart’s research and they all know NTRP is next in line for results. And they are all aware that if Dr. Alkon’s theories are validated and Byrostatin -1 shows efficacy the AD research field will undergo a massive shift in focus.
The Sachs Forum format allowed company CEOs to meet one on one with Pharma and Investment Fund reps. Neurotrope had a number of such meetings with some of the largest Pharma companies in the world.
If the Ph2b results are what we are hoping for I expect that Neurotrope will be swiftly approached by Big Pharma companies who will immediately understand the market implications for Bryostatin.
Sachs Neuroscience Biopartnering & Investment Forum (3-27-17):
Confirmed Attending Companies Include:
A C Binder Corp.
AbbVie, Inc.
Abingworth LLP
Agent Capital, LLC
Alpha Bronze
Amorsa Therapeutics, Inc.
Angel Investor
APS International
Arbor Pharmaceuticals, Inc.
Arix Bioscience
ASDERA
Assembly Biosciences
Athyrium Capital Management
Avanir Pharmaceuticals
Avicenna Ventures
Axial Biotherapeutics
Bigger Capital Fund, LP
Bishop Capital Management
Boehringer Ingelheim Venture USA, Inc.
BrainStorm Cell Therapeutics, Inc.
Brendan E. Cryan & Co. LLC
Cambridge Cognition Ltd.
Cantabio Pharmaceuticals, Inc.
CastleRock Management
CBT Advisors
Cipla New Ventures
Clarus Ventures, LLC
Cognition Therapeutics, Inc.
Cortexyme
CureDuchenne Ventures
Dabar Investment Associates
Daiichi Sankyo, Inc.
Dawson James Securities, Inc.
Deca Ventures
Defined Health, a Cello Health business
Delwar Capital
Edison Investment Research
Eli Lilly and Co.
Embera NeuroTherapeutics, Inc.
Enso Ventures
Erydel
ESC Advisors
Exscientia Ltd.
F. Hoffmann La Roche Ltd.
First Republic Investment Management?
Flagship Ventures
Fountain Healthcare Partners
Fraser Finance
FreeMind Group
Goodwin Procter LLP
Hercules Technology Growth Capital, Inc.
Hereditary Neuropathy Foundation
ICR, Inc.
Johnson & Johnson
Katalyst Securities, LLC
KemPharm, Inc.
K-PAX Pharmaceuticals, Inc.
Landmark Family Office
Lauren Sciences LLC & Maya Sciences LLC
Lexington Capital Management
Little Gem Life Sciences
Lonza Walkersville, Inc.
Loop Capital Markets
Lysosomal Therapeutics, Inc.
M3 Biotechnology, Inc.
Mavericks Capital
MedPro Investors, LLC
Merck & Co., Inc.
Mergermarket
Mid Atlantic Bio Angels
Minoryx Therapeutics S.L.
Mizuho Bank
Momentum Biotech
MP Healthcare Venture Management, Inc.
NeuroRx, Inc.
NeuroTherapia, Inc.
Neurotrope Bioscience, Inc.
New Enterprise Associates
New Frontier Capital, LP
New York Ventures
Nexeon Medsystems, Inc.
NI Research, Inc.
Noble Life Science Partners
NSIP LLC
Occidental Group
Oppenheimer & Co. Inc.
Origenis GmbH
Oryzon Genomics SA
P4G Capital
Park Avenue Capital?
Parkfield Fund LLC
Perseverance Capital
Pfizer, Inc.
Pharmasum Therapeutics AS
PJT Partners
Probiodrug AG
ProMIS™ Neurosciences, Inc.
ProPhase
Purdue Pharma L.P.
Quartet Medicine
Queen Mary University London
Raman Health Technologies, S.L.
Remiges Ventures
Sachs Associates Ltd.
SalubRx Therapeutics, Inc.
Sanofi
Shadow Lake Group, Inc.
Shaw Strategic Capital LLC
Stanphyl Capital
SternAegis Ventures
Sternberg Investments
Sunovion Pharmaceuticals, Inc.
SunRegen Healthcare AG
Syncrosome
Syzygy Therapeutics
T3D Therapeutics, Inc.
Tanaka Capital Management
The Alzheimer's Drug Discovery Foundation
The Astrologers Fund, Inc.
The Center for Performance Investing
The Michael J. Fox Foundation
TikoMed AB
TS Family Office
Union Square Advisors
vasopharm GmbH
Vector Resource Funds
Vista Point Capital
WallachBeth Capital
WBB Securities, LLC
Wells Fargo Advisors
WestPark Capital
Wotczak Group
YLM2012 Trust
Yorkville Advisors, LLC
Yumanity Therapeutics
YunTai Fund USA Office
http://www.sachsforum.com/2nbpi-attendees.html
Recent SNPX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 09:03:21 PM
- Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery • PR Newswire (US) • 05/07/2024 01:00:00 PM
- Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing • PR Newswire (US) • 04/24/2024 01:15:00 PM
- Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics • PR Newswire (US) • 04/09/2024 01:15:00 PM
- Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing • PR Newswire (US) • 04/03/2024 12:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 03:16:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 10:00:18 PM
- Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders • PR Newswire (US) • 12/19/2023 02:00:00 PM
- Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's • PR Newswire (US) • 12/06/2023 02:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 11/14/2023 10:05:18 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/13/2023 10:00:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2023 10:00:23 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/03/2023 09:00:19 PM
- Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology • PR Newswire (US) • 11/02/2023 01:00:00 PM
- Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease • PR Newswire (US) • 09/26/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/22/2023 08:05:55 PM
- Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study • PR Newswire (US) • 09/07/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 09:00:40 PM
- Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis • PR Newswire (US) • 07/19/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/19/2023 12:55:57 PM
- Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience • PR Newswire (US) • 07/13/2023 01:00:00 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM